Table 1.
Baseline demographic and disease characteristicsa
| Characteristic | TACE + thymalfasin (N = 14) | TACE only (N = 14) | Total (N = 28) |
|---|---|---|---|
| Randomized population | |||
| Age, mean (SD), years | 59.2 (9.1) | 60.4 (6.7) | 59.8 (7.9) |
| Male sex, n (%) | 10 (71.4) | 12 (85.7) | 22 (78.6) |
| Race, n (%) | |||
| Asian | 1 (7.1) | 4 (28.6) | 5 (17.9) |
| Black | 3 (21.4) | 2 (14.3) | 5 (17.9) |
| White | 6 (42.9) | 6 (42.9) | 12 (42.9) |
| Hispanic | 2 (14.3) | 2 (14.3) | 4 (14.3) |
| Other | 2 (14.2) | 0 | 2 (7.2) |
| TACE + thymalfasin (N = 14) | TACE only (N = 11) | Total (N = 25) | |
|---|---|---|---|
| MITT population | |||
| Target lesions, median (range), n | 1.50 (1–5) | 2 (1–9) | 2.00 (1–9) |
| Sum of diameters of target lesions, median (range), cm | 11.24 (3.57–22.76) | 7.49 (2.90–60.57) | 10.01 (2.90–60.57) |
| Anti-HCV positive, n (%) | 8 (57) | 6 (55) | 14 (56) |
| HBsAg positive, n (%) | 2 (14) | 1 (9) | 3 (12) |
TACE transarterial chemoembolization, MITT modified intent-to-treat
aDemographic characteristics are described for the randomized population; disease characteristics are described for all treated patients (MITT population)